Purchase this article with an account.
R. Leal Rodríguez, Sr., A. Rodriguez-Castillejos, Sr., M. Martinez-Castellanos, Sr., A. Solis-Vivanco, Sr., D. Ochoa-Contreras, Sr., J. Fromow-Guerra, Sr.; Intravitreal Bevacizumab In Diabetic Macular Edema, Three Years Follow Up. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1355.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To asses our findings in the long term follow up in patients treated for diabetic macular edema (DME) with intravitreal bevacizumab.
A non-randomized, prospective, interventional study which includes patients with DME that received a intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up, OCT and fluorescein angiography)
We included 20 patients that completed three years follow up, 30% males and 70% females, mean age 62.5 years (20 -60 years). Twenty percent improved BCVA , 20 % decreased BCVA and 60% have not showed changes in visual acuity. In the fluorescein angiography collected data, 10 patients presented an improval, one got worst the rest had no changes. Data collected by OCT show a macular thickness' increase in 50%, and macular thickness' decreased in 30% patients, the remaining patients presented no changes.
Clinical Trial: :
This PDF is available to Subscribers Only